-+ 0.00%
-+ 0.00%
-+ 0.00%
BeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion
Share
Listen to the news
BeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion
  • BeOne Medicines posted Q2 revenue of USD 1.71 billion, up 30% year over year; GAAP diluted EPS per ADS rose to USD 2.05.
  • GAAP operating income surged to USD 325.05 million; GAAP net income more than doubled to USD 237.01 million.
  • GAAP gross margin expanded 3 percentage points to 90%; free cash flow climbed to USD 435.34 million.
  • BRUKINSA revenue rose to USD 1.2 billion, up 31%; TEVIMBRA increased to USD 229 million, up 18%.
  • Raised FY 2026 revenue outlook to USD 6.6-6.8 billion; GAAP operating income guidance lifted to USD 1-1.1 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050600BIZWIRE_USPR_____20260805_BW570642) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending